![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Introduction: Long lasting hepatocytes damage related to HCV infection stimulates liver fibrosis resulting in cirrhosis, hepatic failure and hepatocellular carcinoma. Until 2011 the only therapeutic option was 24–48 weeks of pegylated interferon alfa and ribavirin (RBV) with efficacy of 40–70%. New generation of direct-acting antivirals (DAA), available from 2014, can be combined and improve efficacy above 90% with 12 weeks of treatment.
Areas covered: In this article we describe the first registered all-oral regimen consisting of three DAA – ombitasvir (OBV), paritaprevir (PTV) and dasabuvir (DSV) that became available in EU in 2015 to cure patients infected with HCV genotype 1 and 4. We performed a literature search focusing on efficacy and safety data from Phase 1–3 clinical studies and few real-world data.
Expert opinion:OBV/PTV/r±DSV±RBV provided an opportunity to cure almost all patients including cirrhotics and non-responders to previous therapy. This treatment is currently recommended as a first line regimen. However, there is still a need for real-world data. In coming years this medication will probably be replaced with the next DAA generation with improved characteristics such as a shorter treatment duration, improved safety and resistance profile.
Declaration of interest
M Tucejko has received speaker honoraria from Abbvie. R Flisiak has received advisory and speaker honoraria from Abbvie. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Box 1. Drug summary